Value of oral glucose tolerance test in the acute phase of myocardial infarction by Bronisz, Agata et al.
ORIGINAL INVESTIGATION Open Access
Value of oral glucose tolerance test in the acute
phase of myocardial infarction
Agata Bronisz
1, Marek Kozinski
2*, Przemyslaw Magielski
2, Tomasz Fabiszak
2, Joanna Gierach
2, Iwona Swiatkiewicz
2,
Adam Sukiennik
2, Aldona Kubica
3, Marek Bronisz
4, Zofia Grabczewska
2, Anna Sinkiewicz
5, Roman Junik
1,
Jacek Kubica
2
Abstract
Background: Although European guidelines advise oral glucose tolerance test (OGTT) in patients with acute
myocardial infarction (AMI) before or shortly after hospital discharge, data supporting this recommendation are
inconclusive. We aimed to analyze whether disturbances in glucose metabolism diagnosed before hospital
discharge in AMI patients represents a latent pre-existing condition or rather temporary finding. Additionally, we
planned to investigate the value of pre-selected glycemic control parameters as predictors of long-term
glucometabolic state.
Methods: We assessed admission glycemia, glycated hemoglobin, mean blood glucose concentration on days 1
and 2 in 200 patients with a first AMI but without overt disturbances of glucose metabolism. We also performed
OGTT at discharge and 3 months after discharge.
Results: The prevalence of disturbances in glucose metabolism (as assessed by OGTT) at 3 months was
significantly lower than at discharge (29% vs. 48%, p = 0.0001). Disturbances in glucose metabolism were not
confirmed in 63% of patients with impaired glucose tolerance and in 36% of patients with diabetes mellitus
diagnosed during the acute phase of AMI. Age >77 years, glucose ≥12.06 mmol/l at 120 minutes during OGTT
before discharge and mean blood glucose level on day 2 >7.5 mmol/l were identified as independent predictors
of disturbances in glucose metabolism at the 3-month follow-up.
Conclusions: Disturbances in glucose metabolism observed in patients with a first AMI are predominantly
transient. Elderly age, high plasma glucose concentration at 120 minutes during OGTT at discharge and elevated
mean blood glucose level on day 2 were associated with sustained disturbances in glucose metabolism.
Introduction
European guidelines on diabetes, pre-diabetes, and car-
diovascular diseases [1] recommend the performance of
an oral glucose tolerance test (OGTT) in patients with
established cardiovascular disease. Furthermore, the
guidelines on management of acute myocardial infarc-
tion in patients presenting with persistent ST-segment
elevation [2] specify that an OGTT should be performed
before or shortly after hospital discharge. However, data
supporting such suggestions are inconclusive.
Norhammar el al. [ 3 ]s t a t e dt h a td i s t u r b a n c e si ng l u -
cose metabolism diagnosed on the basis of fasting glu-
cose and OGGT in patients with acute myocardial
infarction (AMI) are previously undiagnosed pathologies
related to impairment in b-cell function rather than
stress-induced hyperglycaemia. In the GAMI study [4]
the same research group confirmed that OGTT per-
formed in AMI patients at hospital discharge gives reli-
able information about long-term glucometabolic state.
Conversely, in another Scandinavian study the number
of AMI subjects with disturbances in glucose metabo-
lism on OGTT fell from 46.9% when measured in-
hospital to 24.9% at three months [5].
The aim of our study was to analyze whether distur-
bances in glucose metabolism diagnosed before hospital
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condition or rather temporary finding. Additionally, we
planned the investigation of pre-selected glycaemic con-
trol parameters in terms of their utility as predictors of
long-term glucometabolic state in patients with first
acute myocardial infarction.
Methods
Patients and study design
We conducted a prospective observational cohort study in
consecutive patients with no prior history of diabetes who
were hospitalized between November 2005 and December
2007 for a first episode of ST-segment-elevation acute
myocardial infarction. AMI was diagnosed according to
international recommendations [6]. Exclusion criteria
were: ongoing treatment with catecholamines, glucocorti-
coids or immunosuppressive agents; severe congestive
heart failure (NYHA III and IV); plasma creatinine con-
centration >2 mg/dl; malignant disease or clinically signifi-
cant infection.
Among 261 eligible patients we excluded 61 patients
from the further analysis due to lack of any assessed dia-
betic control parameters (n = 27), unwillingness to par-
ticipate in the study (n = 20), failure to attend the
follow-up appointment (n = 8) and presence of exclu-
sion criteria (n = 6). Therefore, the final sample com-
prised 200 patients.
The following parameters were evaluated: admission
glycaemia in venous blood plasma, glycated hemoglobin
(HbA1c) on day 1, fasting and post-prandial (2 hours
after 3 main meals) capillary blood glucose on day 1
and day 2, as well as 75 g OGTT immediately before
discharge and at 3 months after discharge. Mean blood
glucose concentrations on days 1 and 2 were obtained
from 4 capillary blood samples.
Glucose concentrations were determined using a hex-
okinase method (Glucose kit, Abbott, Lake County,
USA), and an immunoturbidymetric method (Multi-
gent™HbA1c, Seradyn Inc. Indianapolis, USA) was used
to measure HbA1c.
We divided patients into 3 groups on the basis of their
plasma glucose concentration at 120 minutes of OGTT:
normal glucose tolerance (NGT) defined as plasma glu-
cose concentration <7.8 mmol/l; impaired glucose toler-
ance (IGT) defined as plasma glucose concentration
≥7.8 mmol/l but <11.1 mmol/l); new onset diabetes
(DM) defined as plasma glucose concentration ≥11.1
mmol/l. Disturbances in glucose metabolism were
defined as IGT or DM.
During hospitalization we also assessed: total choles-
terol (TC), high density lipoproteins (HDL) and trigly-
cerides (TG) - enzymatic kits by Abbott (Lake County,
USA). LDL concentration was calculated according to
the Friedewald formula.
The study was certified by the local ethics committee.
All participants have given voluntary written informed
consent for inclusion in the study.
Statistical analysis
Use of the Shapiro-Wilk test demonstrated that the
investigated variables were not normally distributed.
Parameters are presented as arithmetic mean (M) ±
standard deviation (SD) for quantitative data or as per-
centage distribution (%) for qualitative attributes. We
applied suitable non-parametric tests (the Mann-
Whitney unpaired rank sum test, the Kruskal-Wallis
unpaired rank sum test, and the Wilcoxon matched-
paired rank sum test) for comparisons of quantitative
dependent and independent variables. For evaluation of
correlations between quantitative variables we used the
Spearman’s correlation coefficient and the test of signifi-
cance for this coefficient. Qualitative data were analyzed
with the c
2 test (including Yates’ correction when indi-
cated) or the McNamara test for unrelated and related
qualitative variables respectively.
We used logistic regression and discriminant analysis
to identify the best predictors for the occurrence of dis-
turbances in glucose metabolism at 3 months after dis-
charge. For specified laboratory tests distinguished by
high discriminative power, receiver operating character-
istic (ROC) curves were drawn in order to estimate their
diagnostic yield. The cut-off value for statistical signifi-
cance was defined as p < 0.05. Statistical analysis was
performed using STATISTICA 8.0 (StatSoft, Tulsa,
United States).
Results
Patients with a pathological result of OGTT 3 months
after AMI were older than patients with NGT. A direct
comparison between patients with NGT and those with
DM at 3 months revealed higher values of admission
glycaemia, HbA1c, mean glycaemia on day 1 and day 2
of hospitalization in diabetic patients. The IGT group
was distinguished from the NTG and DM groups by sig-
nificantly higher mean glycaemia on day 2 and markedly
lower HbA1c level, respectively (Table 1). We found no
differences among the groups in the location of AMI,
treatment course or levels of myocardial necrosis mar-
kers (data not presented).
As presented on Figure 1 disturbances in glucose
metabolism assessed by OGTT were significantly more
frequent before hospital discharge than at 3-months (48
vs. 29%; p = 0.0001). At 3 months there were no distur-
bances in glucose metabolism in 63 and 36% of patients
diagnosed during the acute phase of AMI with IGT and
DM, respectively. In the IGT group disturbances in glu-
cose metabolism persisted f o ra tl e a s t3m o n t h si n3 7 %
of patients, while the incidence of disturbances in
Bronisz et al. Cardiovascular Diabetology 2011, 10:21
http://www.cardiab.com/content/10/1/21
Page 2 of 7Table 1 Baseline characteristics of study groups with normal glucose tolerance, impaired glucose tolerance and
diabetes mellitus as assessed with oral glucose tolerance test at the 3-month follow-up (n = 200)
Overall study
population
N = 200
Normal glucose
tolerance
N = 142
Impaired glucose
tolerance
N=4 8
Diabetes
mellitus
N=1 0
p
Age (years) 56.5 ± 8.7 54.9 ± 8.3 60.6 ± 8.1 59.8 ± 8.7 0.00012*
Male n (%) 155 (77.5) 112 (78.9) 35 (83.3) 8 (80) NS
Body mass index (kg/m
2) 27.0 ± 4.0 26.3 ± 4.1 26.7 ± 4.1 28.9 ± 3.1 NS
Admission glycemia (mmol/l) 7.5 ± 1.6 7.3 ± 1.5 7.8 ± 1.7 8.8 ± 1.9 0.016**
HbA1c (%) 6.0 ± 0.7 6.0 ± 0.7 5.9 ± 0.6 7.1 ± 0.6 0.0001**
0.00006***
Mean blood glycemia on day 1 (mmol/l) 6.5 ± 1.0 6.4 ± 0.9 6.8 ± 0.9 7.8 ± 1.6 0.03**
Mean blood glycemia on day 2 (mmol/l) 6.8 ± 1.0 6.6 ± 0.8 7.3 ± 1.3 7.7 ± 0.7 0.002**
0.0003*
Total cholesterol (mmol/l) 5.8 ± 1.1 5.8 ± 1.1 5.9 ± 1.4 6.0 ± 1.1 NS
LDL cholesterol (mmol/l) 3.9 ± 1.0 3.9 ± 0.9 3.8 ± 1.2 3.8 ± 0.9 NS
HDL cholesterol (mmol/l) 1.4 ± 0.3 1.4 ± 0.3 1.4 ± 0.3 1.3 ± 0.2 NS
Triglycerides (mmol/l) 1.3 ± 1.1 1.2 ± 0.8 1.5 ± 1.6 2.0 ± 1.6 NS
Creatinine (μmol/l) 84.8 ± 15.4 84.8 ± 14.7 83.6 ± 16.8 91.5 ± 18.5 NS
Hypertension (%) 36.5 31.7 47.9 50 NS
Current smoker (%) 70.5 71.8 64.6 80 NS
Family history of premature coronary artery
disease (%)
24.5 26.1 22.9 10 NS
* normal glucose tolerance vs. impaired glucose tolerance, ** normal glucose tolerance vs. diabetes mellitus, *** impaired glucose tolerance vs. diabetes mellitus
HbA1c - glycated hemoglobin.
Figure 1 Prevalence of disturbances in glucose metabolism according to OGTT performed before hospital discharge and after
3 months. OGTT - oral glucose tolerance test.
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was 64% (Table 2).
Patients with an abnormal result of OGTT performed
before discharge but a normal test at 3 months had a
significantly higher mean blood glucose on days 1 and 2
as well as triglyceride concentration when compared to
patients with a normal response to both tests (Table 3).
HbA1c on admission only weakly correlated with plasma
glucose after 2 hours in OGTT performed before dis-
charge (Figure 2). We observed no impact of HbA1c
assessed on admission on the result of OGTT at 3 months.
All variables displaying significant differences among
the subgroups and gender were included into computa-
tional models in order to define independent predictors
for the presence of disturbances in glucose metabolism
3 months after myocardial infarction. In logistic regres-
sion analysis the value of goodness-of fit c2t e s tp<
0.00001 was calculated. The following variables were
found as independent predictors of disturbances in glu-
cose metabolism at 3-month follow-up: age (OR 0.94;
95% CI 0.88-0.99; p < 0.05), glucose concentration at
120 min of OGTT immediately before discharge (OR
0.75; 95% CI 0.628-0.899; p = 0.002) and mean glycaemia
on day 2 (OR 0.44; 95% CI 0.22-0.81; p = 0.009). The dis-
criminative analysis confirmed the above parameters
such as elderly age (p = 0.009), high glucose level at 120
minutes of OGTT before hospital discharge (p < 0.0003)
and elevated mean glycaemia on day 2 (p < 0.05) as
powerful predictors of disturbances in glucose metabo-
lism at the 3-month follow-up. The ROC curve analysis
performed in order to assess diagnostic accuracy for the
prediction of sustained glucometabolic disturbances
revealed area under the curve (AUC) = 0.716 with cut-off
value of 12.056 mmol/l for glucose level at 120 minutes
of OGTT before hospital discharge (p = 0.044), AUC =
0.696 with cut-off value of 77 years for age (p = 0.04) as
well as AUC = 0.727 with cut-off value of 7.514 mmol/l
for mean glycaemia on day 2 (p = 0.045), respectively.
Discussion
Hyperglycemia diagnosed in the peri-infarct period is
clinically highly relevant [7-12]. The prevalence of
disturbances in glucose metabolism in acute myocardial
infarction in our study was 48% which is comparable to
other published data. The Euro Heart Survey [13]
reported the combined incidence of new-onset IGT and
DM to be 58%, while in The China Heart Survey [14] it
was 45% (IGT 24% and DM 21%).
On the other hand, our data indicate significantly
lower rates of DM and IGT at the 3-month follow-up
when compared to the peridischarge period. Therefore,
recommendation in the current guidelines on the per-
formance of OGTT before or shortly after the hospital
discharge might not be applicable to all patients. Simi-
larly, Knudsen et al. [5] found that a substantial number
of patients with abnormal glucose tolerance in the peri-
infarct period had normal glucose tolerance 3 months
after their AMI. However, in the cited study the OGTT
test was performed very early i.e. during the first day
after admission. The divergence between both studies
and the data obtained by Swedish researchers [3,4], who
reported a high reproductability of OGTT performed in
the acute phase of AMI and after 3 months, may derive,
at least partly, from age differences between study
cohorts. Age difference derives from the fact that only
patients with first episode of myocardial infarction were
enrolled into our study. Younger patients, with well pre-
served function of the pancreatic b cells, may develop
disturbances in glucose metabolism only in the setting
of insulin resistance induced by metabolic stress. When
stress is eliminated, the insulin secretion becomes ade-
quate to maintain normal glucose levels. In contrast, in
older populations the gradual degradation of the pan-
creatic b-cells is responsible for disturbances in glucose
metabolism development, which often remains clinically
silent and therefore may be identified only when conco-
mitant ailments (e.g. AMI) occur.
Our doubts concerning the studies conducted by the
Swedish group also result from their other analysis [15]
where they presented a poor reproducibility of OGTT. As
much as 52% of patients of the NGT group at the time of
AMI developed either IGT or DM at the 3-month follow-
up. The coherence in diagnosis of disturbances in glucose
metabolism at discharge and in the 3-month follow-up
Table 2 Results of OGTT immediately before discharge and 3 months after discharge (n = 200)
OGTT immediately before discharge n (%) OGTT 3 months after discharge n (%)
normal glucose tolerance impaired glucose tolerance diabetes mellitus
normal glucose tolerance 104 (52%) * 89 (86%) 15 (14%) -
impaired glucose tolerance 68 (34%) ** 43 (63%) 23 (34%) 2 (3%)
diabetes mellitus 28 (14%) *** 10 (36%) 10 (36%) 8 (28%)
total 200 (100%) 142 (71%) * 48 (24%) ** 10 (5%) ***
p 0.0004 * 0.0001 ** 0.0001 ***
p - for comparison of patients in the particular subgroup immediately before discharge and 3 months after discharge.
OGTT - oral glucose tolerance test.
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found that 3 months after myocardial infarction IGT
appeared in only 14% of patients originally classified as
NGT compared with 86% of subjects who remained free
from disturbances in glucose metabolism. Moreover, none
of the NGT patients developed DM in the course of the 3-
month follow-up.
AMI survivors have considerably higher yearly morbidity
rates of diabetes and impaired fasting glucose than indivi-
duals who have not had an AMI [16]. Therefore, it seems
clinically relevant to identify simple to interpret and feasi-
ble criteria that might predict the persistence of distur-
bances in glucose metabolism after an AMI. According to
our data as well as other previously published works
Table 3 Comparison between patients with an abnormal result of OGTT performed before discharge but a normal test
at 3 months and patients with a normal response to both tests
IGT (n = 43) or DM before discharge
(n = 10) and normal OGTT at 3 months
NGT before discharge and
at 3 months (n = 89)
p
Age (years) 56.0 ± 8.3 54.2 ± 8.4 NS
Male n (%) 39 (73.6) 73 (82.0) NS
Body mass index (kg/m
2) 26.6 ± 5.2 26.1 ± 3.4 NS
Admission glycemia (mmol/l) 7.4 ± 1.5 7.2 ± 1.5 NS
HbA1c (%) 6.2 ± 0.9 5.9 ± 0.5 NS
Mean blood glycemia on day 1 (mmol/l) 6.7 ± 1.0 6.2 ± 0.9 < 0.009
Mean blood glycemia on day 2 (mmol/l) 6.8 ± 0.7 6.4 ± 0.8 < 0.006
Total cholesterol (mmol/l) 5.9 ± 1.0 5.7 ± 1.1 NS
LDL cholesterol (mmol/l) 3.8 ± 0.9 3.9 ± 0.9 NS
HDL cholesterol (mmol/l) 1.4 ± 0.3 1.4 ± 0.3 NS
Triglycerides (mmol/l) 1.5 ± 1.1 1.0 ± 0.5 < 0.002
Creatinine (μmol/l) 85.7 ± 16.4 84.2 ± 13.6 NS
Hypertension (%) 17 (32.1) 28 (31.5) NS
Current smoker (%) 39 (73.6) 63 (70.8) NS
Family history of premature coronary artery disease (%) 16 (30.2) 21 (23.6) NS
Activity of CK-MB on admission (U/l) 52.0 ± 83.2 45.9 ± 58.5 NS
Concentration of troponin I on admission (ng/mL) 1.9 ± 7.0 2.4 ± 7.5 NS
LVEF at discharge (%) 43.4 ± 6.3 44.8 ± 6.5 NS
Heart failure symptoms at discharge (%) 3 (5.7) 3 (3.4) NS
CK-MB - isoenzyme MB of creatine kinase; DM - diabetes mellitus; HbA1c - glycated hemoglobin; IGT - impaired glucose tolerance; LVEF - left ventricular ejection
fraction; NTG - normal glucose tolerance; OGTT - oral glucose tolerance test.
Figure 2 Relations between HbA1c assessed on admission and plasma glucose after 2 hours in OGTT performed before discharge and
at 3 months, respectively. HbA1c - glycated hemoglobin; OGTT - oral glucose tolerance test; RS - the Spearman’s rank correlation coefficient.
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nostic value. We found that the strongest predictor of dis-
turbed glucose metabolisma t3m o n t h sw a sg l u c o s e
concentration >12.06 mmol/l at 120 minutes in the pre-
discharge OGTT. Similarly, Norhammar et al. [3] and
Tenerz et al. [15] found a close correlation between peak
glucose concentration in OGTT performed immediately
before discharge and after 3 months. However, authors of
the first [3] study were unable to establish a cut-off value
for the risk of persistent disturbances in glucose metabo-
lism while in the latter [15] glucose was only measured at
60 minutes in the OGTT. This fact is in contrast to the
statement of World Health Organization [19] that consid-
ers the concentration of glucose at 120 minutes in OGTT
as an essential criterion for diagnosing different forms of
disturbances in glucose metabolism. HbA1c assessment on
admission to hospital as a predictor for previously undiag-
nosed disturbances in glucose metabolism has also been
verified in several studies [3,5,15,17,18]. Nevertheless, their
results are inconclusive. Furthermore, we established
mean blood glucose on day 2 as an independent risk factor
for disturbances in glucose metabolism at 3 month follow-
up. To the best of our knowledge these parameters have
not yet been validated in other studies.
Study limitations
We cannot excluded the possibility that reduction in
daily calorie intake or decrease in daily carbohydrate
consumption within the first days of myocardial infarc-
tion might produce false negative results in OGTT tests
performed in this period. Limited reproducibility of an
OGTT should be also taken into account. Nevertheless
this test remains the most valuable tool for early recog-
nition of individuals with diabetes or at increased risk
for diabetes and heart disease [20].
Conclusions
Disturbances in glucose metabolism observed in patients
with a first AMI are predominantly transient. Elderly
age, high blood glucose concentration at 120 minutes
during OGTT immediately before hospital discharge
and elevated mean blood glucose concentration on day
2 are associated with sustained disturbances in glucose
metabolism.
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